The board of ERIS Lifesciences at its meeting held on 24 November 2025 has approved the acquisition of balance 30% of the total share capital of Swiss Parenterals, a subsidiary of the Company.
Further, the board has approved the issuance of up to 23,06,372 equity
shares of the Company on preferential basis to discharge the consideration for acquisition of 30% stake in Swiss Parenterals.